Cargando…

P994: HEDGEHOG PATHWAY INVOLVEMENT IN MASTOCYTOSIS DEVELOPMENT

Detalles Bibliográficos
Autores principales:	Polivka, L., Parietti, V., Bruneau, J., Soucie, E., Dubreuil, P., Bodemer, C., Hermine, O., Maouche Chretien, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429607/ http://dx.doi.org/10.1097/01.HS9.0000846844.72253.65

Ejemplares similares

Recent advances in the understanding and therapeutic management of mastocytosis
por: Rossignol, Julien, et al.
Publicado: (2019)

994. Risk for Viral Rebound in the Era of U=U; A CNICS Analysis
por: Hansen, Blake, et al.
Publicado: (2020)

P1006: NEXT GENERATION SEQUENCING (NGS) IN PEDIATRIC MASTOCYTOSIS
por: Angi, A., et al.
Publicado: (2022)

P994: GERMLINE SINGLE-NUCLEOTIDE VARIANTS (SNV) IN THE JAK-STAT PATHWAY GENOME OF ADOLESCENT AND YOUNG ADULTS (AYA) AND NON-AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)
por: Diepers, Alice, et al.
Publicado: (2023)

P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS
por: Mancini, M., et al.
Publicado: (2022)

P1038: CLINICOPATHOLOGIC AND MOLECULAR CORRELATES OF ORGAN DAMAGE ACROSS THE SPECTRUM OF ADVANCED SYSTEMIC MASTOCYTOSIS
por: Liang, E., et al.
Publicado: (2022)

Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset
por: Lanternier, Fanny, et al.
Publicado: (2008)

An elusive case of systemic mastocytosis
por: Lee, JK, et al.
Publicado: (2010)

P1580: MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS DURING THE COVID-19 PANDEMIC: A SINGLE CENTER EXPERIENCE
por: Filipponi, V., et al.
Publicado: (2022)

P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023)

P1365: HUMAN CD117 AS AN IMMUNOTHERAPEUTIC TARGET IN PRECLINICAL MODELS OF ADVANCED SYSTEMIC MASTOCYTOSIS
por: Kaiser, Anne, et al.
Publicado: (2023)

Adverse reactions to food in patients with mastocytosis
por: Pucino, Valentina, et al.
Publicado: (2011)

Targeted Treatment Options in Mastocytosis
por: Vaes, Mélanie, et al.
Publicado: (2017)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
por: Reiter, A., et al.
Publicado: (2022)

Pion-deuteron elastic differential corss-section at 994 MeV/c
por: Bradamante, Franco, et al.
Publicado: (1969)

Association of mastocytosis with interleukin 31 gene polymorphism
por: Nedoszytko, Boguslaw, et al.
Publicado: (2015)

P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP
por: Gotlib, Jason, et al.
Publicado: (2023)

Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients
por: Rouet, Audrey, et al.
Publicado: (2016)

Pion-deuteron elastic differential cross-section at 994 MeV/c
por: Bradamante, F, et al.
Publicado: (1969)

994. Comparison of Lactate, Procalcitonin and a Gene Signature Assay Alone or in Combination to Differentiate Sepsis from Non-infectious Systemic Inflammation in ICU Patients
por: Hassan, Erkan, et al.
Publicado: (2021)

P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES
por: George, T., et al.
Publicado: (2022)

P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL
por: Gotlib, Jason, et al.
Publicado: (2023)

P996: UTILITY OF KIT P.D816 IN MYELOID NEOPLASM WITHOUT DOCUMENTED SYSTEMIC MASTOCYTOSIS TO DETECT HIDDEN MAST CELLS IN BONE MARROW
por: Kim, D. H., et al.
Publicado: (2022)

P21 - Evaluation of modifications in SCORMA Index and grading in the follow-up of a pediatric population with mastocytosis
por: Del Mastro, Andrea, et al.
Publicado: (2014)

Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris, Marie Olivia, et al.
Publicado: (2017)

P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

P691: MULTIOMIC SINGLE-CELL APPROACH REVEALED CLONAL ARCHITECTURE OF KIT MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS WITH/WITHOUT SYSTEMIC MASTOCYTOSIS
por: Wang, Yu-Hung, et al.
Publicado: (2023)

ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases
por: Damaj, Gandhi, et al.
Publicado: (2014)

Induction of apoptosis in rat peripheral blood lymphocytes by the anticancer drug CI-994 (acetyldinaline)
por: Graziano, Michael J, et al.
Publicado: (2001)

994 Human Parechovirus Type 3 Infection as a Cause of Apnea in Premature Infants
por: Nirei, Jun, et al.
Publicado: (2014)

P1017: HARBOR: A PHASE 2/3 STUDY OF BLU-263 IN PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS AND MONOCLONAL MAST CELL ACTIVATION SYNDROME
por: Castells, M., et al.
Publicado: (2022)

Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis
por: Hermine, Olivier, et al.
Publicado: (2008)

Neuroimaging evidence of brain abnormalities in mastocytosis
por: Boddaert, N, et al.
Publicado: (2017)

The care pathway for children with urticaria, angioedema, mastocytosis
por: Ferrante, Giuliana, et al.
Publicado: (2015)

Melanoma and Mastocytosis
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Respiratory involvement in juvenile dermatomyositis
por: Fabi, M, et al.
Publicado: (2008)

Proposal for the award of a contract for civil-engineering work for the construction of the new Buildings 989, 990 and 994
Publicado: (2017)

POS-994 ANTIBODY RESPONSE TO COVID 19 VACCINATION IN CHRONIC KIDNEY DISEASE PATIENTS ON MAINTENANCE HEMODIALYSIS
por: AKHIL, M.S., et al.
Publicado: (2022)

Covid-19 hospital mortality using spatial hierarchical models: cohort design with 74,994 registers
por: Chiaravalloti, Francisco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fv1jujlkcea2brhhb1tshuerv6